Steven Kao

1.9k total citations · 1 hit paper
42 papers, 1.3k citations indexed

About

Steven Kao is a scholar working on Pulmonary and Respiratory Medicine, Oncology and Radiology, Nuclear Medicine and Imaging. According to data from OpenAlex, Steven Kao has authored 42 papers receiving a total of 1.3k indexed citations (citations by other indexed papers that have themselves been cited), including 30 papers in Pulmonary and Respiratory Medicine, 23 papers in Oncology and 6 papers in Radiology, Nuclear Medicine and Imaging. Recurrent topics in Steven Kao's work include Occupational and environmental lung diseases (16 papers), Lung Cancer Treatments and Mutations (15 papers) and Pleural and Pulmonary Diseases (11 papers). Steven Kao is often cited by papers focused on Occupational and environmental lung diseases (16 papers), Lung Cancer Treatments and Mutations (15 papers) and Pleural and Pulmonary Diseases (11 papers). Steven Kao collaborates with scholars based in Australia, United States and Japan. Steven Kao's co-authors include Nico van Zandwijk, Janette L. Vardy, Glen Reid, Stephen Clarke, Wendy A. Cooper, Michael Boyer, Anthony Linton, Nick Pavlakis, Agata Chrzanowska and David Adams and has published in prestigious journals such as Journal of Clinical Oncology, Cancer Research and The Lancet Oncology.

In The Last Decade

Steven Kao

39 papers receiving 1.3k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Safety and activity of microRNA-loaded minicells in patients with recurrent malignant pleural mesothelioma: a first-in-man, phase 1, open-label, dose-escalation study

2017 539 citations Nico van Zandwijk, Nick Pavlakis et al. The Lancet Oncology profile →

Peers

Countries citing papers authored by Steven Kao

Since Specialization

Citations

This map shows the geographic impact of Steven Kao's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Steven Kao with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Steven Kao more than expected).

Fields of papers citing papers by Steven Kao

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Steven Kao. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Steven Kao. The network helps show where Steven Kao may publish in the future.

Co-authorship network of co-authors of Steven Kao

This figure shows the co-authorship network connecting the top 25 collaborators of Steven Kao. A scholar is included among the top collaborators of Steven Kao based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Steven Kao. Steven Kao is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Second-line treatment strategies and clinical outcomes after progression on chemoimmunotherapy in extensive-stage small-cell lung cancer 2025 ·Lung Cancer ·(unknown), Martin Faltys, Marliese Alexander, (unknown), Sagun Parakh, (unknown), Lydia Warburton, A Fantoni, Timothy Clay, Surein Arulananda, (unknown), Steven Kao, Ivan Da Silva, Lauren Brown, Brett Hughes, (unknown), Benjamin Solomon, Thomas John	0
2	Variations in Patterns of Prescribing Durvalumab in Stage III Lung Cancer: A Survey of Australian Medical Oncologists 2024 ·Oncology ·(unknown), Victoria Bray, Deme Karikios, (unknown), Shalini Subramaniam, (unknown), Steven Kao, (unknown)	2
3	Real world efficacy and toxicity of consolidation durvalumab following chemoradiotherapy in older Australian patients with unresectable stage III non-small cell lung cancer 2024 ·Journal of Geriatric Oncology ·(unknown), (unknown), (unknown), (unknown), Victoria Bray, (unknown), Po Yee Yip, Anthony Linton, Prunella Blinman, Adnan Nagrial, Jenny Lee, Michael Boyer, Steven Kao	7
4	The emerging role of the lung microbiome and its importance in non-small cell lung cancer diagnosis and treatment 2022 ·Lung Cancer ·Anna McLean, Steven Kao, David Barnes, Keith Wong, Richard A. Scolyer, Wendy A. Cooper, Maija R.J. Kohonen‐Corish	26
5	Standard-Dose Osimertinib in EGFR-Mutated Non–Small-Cell Lung Adenocarcinoma With Leptomeningeal Disease 2021 ·JCO Precision Oncology ·(unknown), (unknown), Sagun Parakh, Steven Kao, Craig Lewis, Melvin Chin, Mark Voskoboynik, Malinda Itchins, Ross Jennens, A. Broad, (unknown), Benjamin Solomon	4
6	Why do delays to diagnosis and treatment of lung cancer occur? A mixed methods study of insights from Australian clinicians 2020 ·Asia-Pacific Journal of Clinical Oncology ·(unknown), Haryana M. Dhillon, (unknown), Prunella Blinman, Steven Kao, Janette L. Vardy	3
7	Prolonged Disease Control on Nivolumab for Primary Pulmonary NUT Carcinoma 2020 ·Clinical Lung Cancer ·(unknown), Annabelle Mahar, (unknown), (unknown), Steven Kao	12
8	A survey of patient and caregiver experience with malignant pleural mesothelioma 2019 ·Supportive Care in Cancer ·(unknown), Haryana M. Dhillon, Steven Kao, Janette L. Vardy	25
9	Patterns of care and survival of older patients with malignant pleural mesothelioma 2019 ·Journal of Geriatric Oncology ·Anthony Linton, (unknown), Steven Kao, Nico van Zandwijk	3
10	How long is too long? A scoping review of health system delays in lung cancer 2018 ·European Respiratory Review ·(unknown), (unknown), Prunella Blinman, Steven Kao, Haryana M. Dhillon, Janette L. Vardy	57
11	Certainty within uncertainty: a qualitative study of the experience of metastatic melanoma patients undergoing pembrolizumab immunotherapy 2018 ·Supportive Care in Cancer ·David Levy, Haryana M. Dhillon, Anna J. Lomax, Michael Marthick, Catriona M. McNeil, Steven Kao, Judith Lacey	54
12	A supportive care intervention for people with metastatic melanoma being treated with immunotherapy: a pilot study assessing feasibility, perceived benefit, and acceptability 2018 ·Supportive Care in Cancer ·Judith Lacey, Anna J. Lomax, Catriona M. McNeil, Michael Marthick, David Levy, Steven Kao, (unknown), Haryana M. Dhillon	34
13	P3.03-033 The Influence of Geographic and Socioeconomic Factors on Prognosis and Treatment Provision in Malignant Pleural Mesothelioma 2017 ·Journal of Thoracic Oncology ·Anthony Linton, Matthew Soeberg, Steven Kao, Richard Broome, Nico van Zandwijk	1
14	Safety and activity of microRNA-loaded minicells in patients with recurrent malignant pleural mesothelioma: a first-in-man, phase 1, open-label, dose-escalation study breakdown → 2017 ·The Lancet Oncology ·Nico van Zandwijk, Nick Pavlakis, Steven Kao, Anthony Linton, Michael Boyer, Stephen Clarke, Y. Wendy Huynh, Agata Chrzanowska, Michael Fulham, Dale L. Bailey, Wendy A. Cooper, Leonard Kritharides, Lloyd J Ridley, Scott Pattison, Jennifer A. MacDiarmid, Himanshu Brahmbhatt, Glen Reid	539
15	Pathological complete response in malignant pleural mesothelioma patients following induction chemotherapy: Predictive factors and outcomes 2017 ·Lung Cancer ·(unknown), Sanjeev Kumar, Tristan D. Yan, (unknown), Catherine J. Kennedy, Jocelyn McLean, Michael Boyer, Brian C. McCaughan, Steven Kao	4
16	Geographic and socioeconomic factors in patients with malignant pleural mesothelioma in New South Wales and their impact upon clinical outcomes 2017 ·Respirology ·Anthony Linton, Matthew Soeberg, Richard Broome, Steven Kao, Nico van Zandwijk	6
17	A proteomics-based approach identifies secreted protein acidic and rich in cysteine as a prognostic biomarker in malignant pleural mesothelioma 2016 ·British Journal of Cancer ·Steven Kao, Michaela B. Kirschner, Wendy A. Cooper, Trần Nam Thắng, Sjaak Burgers, Casey M. Wright, (unknown), Daan van den Broek, J. James Edelman, Michael P. Vallely, Brian C. McCaughan, Nick Pavlakis, Stephen Clarke, Mark P. Molloy, Nico van Zandwijk, Glen Reid	20
18	Use of cancer therapy at the end of life in patients with malignant pleural mesothelioma 2013 ·Supportive Care in Cancer ·Steven Kao, Nico van Zandwijk, Peter Corte, Christopher Clarke, Stephen Clarke, Janette L. Vardy	7
19	Malignant mesothelioma 2010 ·Internal Medicine Journal ·Steven Kao, Glen Reid, (unknown), Janette L. Vardy, Stephen Clarke, Nico van Zandwijk	24
20	Use of chemotherapy at end of life in oncology patients 2009 ·Annals of Oncology ·Steven Kao, Jesmin Shafiq, Janette L. Vardy, David Adams	129

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact